{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:04:00Z","timestamp":1772453040461,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Gerontol Geriat"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00391-026-02558-1","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:48:12Z","timestamp":1771516092000},"page":"148-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmakokinetik und -dynamik der Anti-Parkinson-Medikamente beim geriatrischen Patienten","Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients"],"prefix":"10.1007","volume":"59","author":[{"given":"Marija","family":"Djukic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sch\u00fctze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Yoshida-Stiksrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orkhan","family":"Ismayilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-995X","authenticated-orcid":false,"given":"Roland","family":"Nau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2558_CR1","volume":"9","author":"SH Isaacson","year":"2023","unstructured":"Isaacson\u00a0SH, Hauser\u00a0RA, Pahwa\u00a0R et\u00a0al (2023) Dopamine agonists in Parkinson\u2019s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. Clin Park Relat Disord 9:100212","journal-title":"Clin Park Relat Disord"},{"key":"2558_CR2","first-page":"412","volume":"122","author":"M Djukic","year":"2025","unstructured":"Djukic\u00a0M, Yoshida-Stiksrud\u00a0E, Nau\u00a0R (2025) The Treatment of Older Patients with Parkinson\u2019s Disease. Dtsch Arztebl Int 122:412\u2013418","journal-title":"Dtsch Arztebl Int"},{"key":"2558_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40266-025-01257-7","volume":"42","author":"F Pazan","year":"2025","unstructured":"Pazan\u00a0F, Weiss\u00a0C, Wehling\u00a0M, FORTA (2025) The FORTA (Fit for the Aged) List 2024: Fifth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults. Drugs Aging 42:1197\u20131199","journal-title":"Drugs Aging"},{"key":"2558_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/00003088-198713030-00002","volume":"13","author":"JM Cedarbaum","year":"1987","unstructured":"Cedarbaum\u00a0JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13:141\u2013178","journal-title":"Clin Pharmacokinet"},{"key":"2558_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","volume":"45","author":"D Nyholm","year":"2006","unstructured":"Nyholm\u00a0D (2006) Pharmacokinetic optimisation in the treatment of Parkinson\u2019s disease: an update. Clin Pharmacokinet 45:109\u2013136","journal-title":"Clin Pharmacokinet"},{"key":"2558_CR6","first-page":"37","volume":"89","author":"JA Borovac","year":"2016","unstructured":"Borovac\u00a0JA (2016) Side effects of a\u00a0dopamine agonist therapy for Parkinson\u2019s disease: a\u00a0mini-review of clinical pharmacology. Yale J Biol Med 89:37\u201347","journal-title":"Yale J Biol Med"},{"key":"2558_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mds.1203","volume":"16","author":"R Hardoff","year":"2001","unstructured":"Hardoff\u00a0R, Sula\u00a0M, Tamir\u00a0A et\u00a0al (2001) Gastric emptying time and gastric motility in patients with Parkinson\u2019s disease. Mov Disord 16:1041\u20131047","journal-title":"Mov Disord"},{"key":"2558_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/ncn3.152","volume":"3","author":"H Iwaki","year":"2015","unstructured":"Iwaki\u00a0H, Nishikawa\u00a0N, Nagai\u00a0M et\u00a0al (2015) Pharmacokinetics of levodopa\/benserazide versus levodopa\/carbidopa in healthy subjects and patients with Parkinson\u2019s disease. Neurology and Clinical Neuroscience 3:68\u201373","journal-title":"Neurology and Clinical Neuroscience"},{"key":"2558_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ana.410200212","volume":"20","author":"KL Leenders","year":"1986","unstructured":"Leenders\u00a0KL, Poewe\u00a0WH, Palmer\u00a0AJ et\u00a0al (1986) Inhibition of L\u2011[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20:258\u2013262","journal-title":"Ann Neurol"},{"key":"2558_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt\u00a0PA, Hauser\u00a0RA, Pahwa\u00a0R et\u00a0al (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18:145\u2013154","journal-title":"Lancet Neurol"},{"key":"2558_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40262-015-0265-3","volume":"54","author":"AA Othman","year":"2015","unstructured":"Othman\u00a0AA, Chatamra\u00a0K, Mohamed\u00a0ME et\u00a0al (2015) Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in Japanese subjects with advanced Parkinson\u2019s disease: pharmacokinetics and pilot efficacy and safety. Clin Pharmacokinet 54:975\u2013984","journal-title":"Clin Pharmacokinet"},{"key":"2558_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2022.03.012","volume":"97","author":"M Rosebraugh","year":"2022","unstructured":"Rosebraugh\u00a0M, Stodtmann\u00a0S, Liu\u00a0W et\u00a0al (2022) Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord 97:68\u201372","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 2","key":"2558_CR13","first-page":"25","volume":"39","author":"KC Yeh","year":"1989","unstructured":"Yeh\u00a0KC, August\u00a0TF, Bush\u00a0DF et\u00a0al (1989) Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39(Suppl 2):25\u201338","journal-title":"Neurology"},{"key":"2558_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost\u00a0ST, Kaldenbach\u00a0MA, Antonini\u00a0A et\u00a0al (2023) Levodopa Dose Equivalency in Parkinson\u2019s Disease: Updated Systematic Review and Proposals. Mov Disord 38:1236\u20131252","journal-title":"Mov Disord"},{"key":"2558_CR15","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta\u00a0V, Klingelhoefer\u00a0L, Longardner\u00a0K et\u00a0al (2023) Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur J Neurol 30:1465\u20131480","journal-title":"Eur J Neurol"},{"key":"2558_CR16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00702-024-02828-5","volume":"131","author":"T M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0T, Gerlach\u00a0M, Hefner\u00a0G et\u00a0al (2024) Therapeutic drug monitoring in Parkinson\u2019s disease. J\u00a0Neural Transm (Vienna) 131:1247\u20131262","journal-title":"J Neural Transm (Vienna)"},{"key":"2558_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00002018-199614050-00006","volume":"14","author":"RF Pfeiffer","year":"1996","unstructured":"Pfeiffer\u00a0RF (1996) Antiparkinsonian agents: drug interactions of clinical significance. Drug Saf 14:343\u2013354","journal-title":"Drug Saf"},{"key":"2558_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1212\/WNL.31.2.215","volume":"31","author":"T Eisler","year":"1981","unstructured":"Eisler\u00a0T, Eng\u00a0N, Plotkin\u00a0C, Calne\u00a0DB (1981) Absorption of levodopa after rectal administration. Neurology 31:215\u2013217","journal-title":"Neurology"},{"key":"2558_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.31486\/toj.24.0103","volume":"25","author":"A Guthrie","year":"2025","unstructured":"Guthrie\u00a0A, King\u00a0J, Casey\u00a0A (2025) Rectal Administration of Carbidopa\/Levodopa. Ochsner J 25:114\u2013115","journal-title":"Ochsner J"},{"key":"2558_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000441489","volume":"7","author":"JM Vogelzang","year":"2015","unstructured":"Vogelzang\u00a0JM, Luinstra\u00a0M, Rutgers\u00a0AW (2015) Effect of Rectal Levodopa Administration: A Case Report. Case Rep Neurol 7:209\u2013212","journal-title":"Case Rep Neurol"},{"issue":"5694","key":"2558_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/bmj.1.5694.474","volume":"1","author":"DB Calne","year":"1970","unstructured":"Calne\u00a0DB, Brennan\u00a0J, Spiers\u00a0AS et\u00a0al (1970) Hypotension caused by L\u2011dopa. Br Med J 1(5694):474\u2013475","journal-title":"Br Med J"},{"key":"2558_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105860","volume":"115","author":"Z Liu","year":"2023","unstructured":"Liu\u00a0Z, Su\u00a0D, Zhou\u00a0J et\u00a0al (2023) Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson\u2019s disease: Results of acute levodopa challenge test. Parkinsonism Relat Disord 115:105860","journal-title":"Parkinsonism Relat Disord"},{"key":"2558_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081658","volume":"14","author":"L Breuil","year":"2022","unstructured":"Breuil\u00a0L, Goutal\u00a0S, Marie\u00a0S et\u00a0al (2022) Comparison of the Blood-Brain Barrier Transport and Vulnerability to P\u2011Glycoprotein-Mediated Drug-Drug Interaction of Domperidone versus Metoclopramide Assessed Using In Vitro Assay and PET Imaging. Pharmaceutics 14:1658","journal-title":"Pharmaceutics"},{"key":"2558_CR24","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1111\/bcp.13708","volume":"84","author":"M Simeonova","year":"2018","unstructured":"Simeonova\u00a0M, de Vries\u00a0F, Pouwels\u00a0S et\u00a0al (2018) Increased risk of all-cause mortality associated with domperidone use in Parkinson\u2019s patients: A population-based cohort study in the UK. Br J Clin Pharmacol 84:2551\u20132561","journal-title":"Br J Clin Pharmacol"},{"key":"2558_CR25","unstructured":"H\u00f6glinger G., Trenkwalder C. et al., Parkinson-Krankheit, S2k-Leitlinie,2023, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcrDiagnostik und Therapie in der Neurologie. Online: www.dgn.org\/leitlinien (abgerufen am 3.2.2026)"},{"key":"2558_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/14737175.2021.1968298","volume":"21","author":"P Jenner","year":"2021","unstructured":"Jenner\u00a0P, Rocha\u00a0JF, Ferreira\u00a0JJ et\u00a0al (2021) Redefining the strategy for the use of COMT inhibitors in Parkinson\u2019s disease: the role of opicapone. Expert Rev Neurother 21:1019\u20131033","journal-title":"Expert Rev Neurother"},{"key":"2558_CR27","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1345\/aph.19328","volume":"34","author":"BS Chong","year":"2000","unstructured":"Chong\u00a0BS, Mersfelder\u00a0TL (2000) Entacapone. Ann Pharmacother 34:1056\u20131065","journal-title":"Ann Pharmacother"},{"key":"2558_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00003495-199958010-00017","volume":"58","author":"KJ Holm","year":"1999","unstructured":"Holm\u00a0KJ, Spencer\u00a0CM (1999) Entacapone: a review of its use in Parkinson\u2019s disease. Drugs 58:159\u2013177","journal-title":"Drugs"},{"key":"2558_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2146\/ajhp050395","volume":"63","author":"JJ Chen","year":"2006","unstructured":"Chen\u00a0JJ, Ly\u00a0AV (2006) Rasagiline: A second-generation monoamine oxidase type\u2011B inhibitor for the treatment of Parkinson\u2019s disease. Am J Health Syst Pharm 63:915\u2013928","journal-title":"Am J Health Syst Pharm"},{"key":"2558_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/clpt.1994.204","volume":"56","author":"EH Heinonen","year":"1994","unstructured":"Heinonen\u00a0EH, Anttila\u00a0MI, Lammintausta\u00a0RA (1994) Pharmacokinetic aspects of l\u2011deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742\u2013749","journal-title":"Clin Pharmacol Ther"},{"key":"2558_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.9740\/mhc.2017.11.262","volume":"7","author":"JJ Chen","year":"2018","unstructured":"Chen\u00a0JJ (2018) Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin 7:262\u2013270","journal-title":"Ment Health Clin"},{"key":"2558_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-015-0377-y","volume":"75","author":"JP Elshoff","year":"2015","unstructured":"Elshoff\u00a0JP, Cawello\u00a0W, Andreas\u00a0JO et\u00a0al (2015) An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson\u2019s disease and restless legs syndrome. Drugs 75:487\u2013501","journal-title":"Drugs"},{"key":"2558_CR33","volume":"10","author":"HF Wu","year":"2024","unstructured":"Wu\u00a0HF, Yu\u00a0ELM, Sheng\u00a0B et\u00a0al (2024) Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson\u2019s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better? Clin Park Relat Disord 10:100235","journal-title":"Clin Park Relat Disord"},{"key":"2558_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ana.25923","volume":"89","author":"AJ Espay","year":"2021","unstructured":"Espay\u00a0AJ, Marsili\u00a0L, Mahajan\u00a0A et\u00a0al (2021) Rivastigmine in Parkinson\u2019s Disease Dementia with Orthostatic Hypotension. Ann Neurol 89:91\u201398","journal-title":"Ann Neurol"},{"key":"2558_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson\u00a0EJ, Lord\u00a0SR, Brodie\u00a0MA et\u00a0al (2016) Rivastigmine for gait stability in patients with Parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:249\u2013258","journal-title":"Lancet Neurol"}],"container-title":["Zeitschrift f\u00fcr Gerontologie und Geriatrie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-026-02558-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00391-026-02558-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-026-02558-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:13:42Z","timestamp":1772450022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00391-026-02558-1"}},"subtitle":["Schl\u00fcssel zur Optimierung der Therapie","Key for optimization of treatment"],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2558"],"URL":"https:\/\/doi.org\/10.1007\/s00391-026-02558-1","relation":{},"ISSN":["0948-6704","1435-1269"],"issn-type":[{"value":"0948-6704","type":"print"},{"value":"1435-1269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"M.\u00a0Djukic\n                      : A.\u00a0Finanzielle Interessen: M.\u00a0Djukic gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte Chef\u00e4rztin im Evangelischen Krankenhaus Weende, Abt. f\u00fcr Geriatrie, G\u00f6ttingen | Mitgliedschaften: DGG, DGN | Ehemaliges Vorstandsmitglied DGG.\n                      S.\u00a0Sch\u00fctze\n                      : A.\u00a0Finanzielle Interessen: S.\u00a0Sch\u00fctze gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Fach\u00e4rztin f\u00fcr Neurologie mit Zusatzbezeichnung Geriatrie, Chef\u00e4rztin der Medizinisch-Geriatrischen Klinik der AGAPLESION Frankfurter Diakonie Kliniken, | Vorstandsmitglied der Deutschen Gesellschaft f\u00fcr Geriatrie (DGG, Schatzmeisterin), Leiterin der AG Demenz und Delir der DGG, Mitglied der DRG-Fachgruppe von BVG, DGG und DGGG, | Mitgliedschaften: DGG, Deutsche Gesellschaft f\u00fcr Neurologie (DGN).\n                      E.\u00a0Yoshida-Stiksrud\n                      : A.\u00a0Finanzielle Interessen: E.\u00a0Yoshida-Stiksrud gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte \u00c4rztin Universit\u00e4tsmedizin G\u00f6ttingen und Ev. Krankenhaus G\u00f6ttingen-Weende | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Schlafmedizin, Deutsche Gesellschaft f\u00fcr klinische Neurophysiologie, Deutsche Gesellschaft f\u00fcr Epileptologie, AG Tiefe Hirnstimulation, Marburger Bund.\n                      O.\u00a0Ismayilov\n                      : A.\u00a0Finanzielle Interessen: O.\u00a0Ismayilov gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellter Neurologe mit Zusatzbezeichnung Geriatrie und Intensivmedizin, Oberarzt der medizinisch-geriatrischen Klinik, Agaplesion Markus Krankenhaus, Frankfurt am Main | Mitgliedschaften: DGN, DGG.\n                      R.\u00a0Nau\n                      : A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung projektbezogen: Novartis, B. Braun Melsungen, Strathmann, Tillotts, Deutsche Gesellschaft f\u00fcr Geriatrie, Innovationsausschuss ReToCdiff (01VSF16059).\u00a0\u2013 Vortragshonorare und Reisekostenerstattungen: Bayer Vital, Pfizer, Bristol-Myers Squibb, Novartis, Otto-Loewi-Stiftung, Tillotts.\u00a0\u2013 Glaxo Smith Kline, Aktien.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Arzt f\u00fcr Neurologie und Psychiatrie, Zusatzweiterbildung Geriatrie im Ruhestand; teilzeitbesch\u00e4ftigt im Ev. Krankenhaus G\u00f6ttingen-Weende | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Geriatrie, Deutsche Gesellschaft f\u00fcr Neurologie, Deutsche Gesellschaft f\u00fcr Infektiologie, Deutsche Gesellschaft f\u00fcr Liquordiagnostik und Klinische Neurochemie, European Society for Clinical Microbiology and Infectious Diseases, Paul-Ehrlich-Gesellschaft f\u00fcr Infektionstherapie, Verein Demokratischer \u00c4rztinnen und \u00c4rzte, Ver.Di, Walter-Marget-Vereinigung zur F\u00f6rderung der Infektiologie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}